Trials / Completed
CompletedNCT02007317
Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study
A Single Center, Open Label Study for Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R in Patients With Basal Cell Carcinoma (BCC) Prior to Tumor Excision- a Phase II Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Oshadi Drug Administration · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
This study is single-arm, none randomized, open label, two-dose-cohorts, single center clinical trial for evaluation of the safety and efficacy of Oshadi D and Oshadi R in patients with BCC. Patients will receive Oshadi D and Oshadi R for 60 -90 days until the planned surgical excision of the lesion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oshadi D & Oshadi R | Anti tumor agents |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2017-03-01
- Completion
- 2017-03-01
- First posted
- 2013-12-10
- Last updated
- 2018-04-18
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT02007317. Inclusion in this directory is not an endorsement.